These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16213413)

  • 1. Evolution of biomarkers: drug discovery to personalized medicine.
    Mukhtar M
    Drug Discov Today; 2005 Sep; 10(18):1216-8. PubMed ID: 16213413
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges of drug discovery for personalized medicine.
    Jain KK
    Curr Opin Mol Ther; 2006 Dec; 8(6):487-92. PubMed ID: 17243483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine.
    Garrison LP; Austin MJ
    Health Aff (Millwood); 2006; 25(5):1281-90. PubMed ID: 16966724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine.
    Zineh I; Huang SM
    Biomark Med; 2011 Dec; 5(6):705-13. PubMed ID: 22103607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized pharmacotherapy: genotypes, biomarkers, and beyond.
    Gurwitz D; Lunshof JE
    Clin Pharmacol Ther; 2009 Feb; 85(2):142. PubMed ID: 19005463
    [No Abstract]   [Full Text] [Related]  

  • 7. The future of biomarkers.
    Aruoma OI; Bahorun T
    Toxicology; 2010 Dec; 278(2):161-4. PubMed ID: 20888386
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer biomarkers: current issues and future directions.
    Jain KK
    Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational medicine: the discovery of bridging biomarkers using pharmacogenomics.
    Mendrick DL
    Pharmacogenomics; 2006 Sep; 7(6):943-7. PubMed ID: 16981852
    [No Abstract]   [Full Text] [Related]  

  • 11. Is personalized medicine finally arriving?
    Allison M
    Nat Biotechnol; 2008 May; 26(5):509-17. PubMed ID: 18464779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State and federal legislation in personalized medicine.
    Raich T; Irwin J
    MLO Med Lab Obs; 2007 Aug; 39(8):48. PubMed ID: 17867420
    [No Abstract]   [Full Text] [Related]  

  • 13. The genomics and Personalized Medicine Act of 2006.
    Obama B
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):39-40. PubMed ID: 17339825
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of the human genome on the discovery of immune-modulatory therapeutics.
    Manning AM
    Curr Opin Investig Drugs; 2006 May; 7(5):406-11. PubMed ID: 16729715
    [No Abstract]   [Full Text] [Related]  

  • 15. Personalized medicine complicates medical decision-making.
    Morrow T
    Manag Care; 2008 Feb; 17(2):59-60. PubMed ID: 18361260
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of ex vivo systems for biomarker discovery.
    Lavallie ER; Dorner AJ; Burczynski ME
    Curr Opin Pharmacol; 2008 Oct; 8(5):647-53. PubMed ID: 18771752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenetics: towards personalized medicine].
    Gurwitz D; Rehavi M
    Harefuah; 2005 Oct; 144(10):711-6, 750. PubMed ID: 16281764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding a liability-free space in which personalized medicine can bloom.
    Evans BJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):461-5. PubMed ID: 17713468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
    Karsdal MA; Henriksen K; Leeming DJ; Mitchell P; Duffin K; Barascuk N; Klickstein L; Aggarwal P; Nemirovskiy O; Byrjalsen I; Qvist P; Bay-Jensen AC; Dam EB; Madsen SH; Christiansen C
    Biomarkers; 2009 May; 14(3):181-202. PubMed ID: 19399662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.